Novartis' Kymriah, or tisagenlecleucel, was recommended by the UK's National Institute for Health and Care Excellence for use in patients younger than 25 who have relapsed or refractory B-cell acute lymphoblastic leukemia. The drug will be funded by the National Health Service through the Cancer Drugs Fund.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.